Telesis Bio 

$0.001000
24
-$0.00-0% Tuesday 20:00

Statistics

Day High
0.01155
Day Low
0.01155
52W High
0.3
52W Low
0.0001
Volume
3
Avg. Volume
487
Mkt Cap
1,776
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

8MayExpected
Q1 2023
Q2 2023
Q3 2023
Q1 2024
Q2 2024
Q3 2024
Q1 2025
-7.62
-5.08
-2.54
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-178.21%Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
55.02MRevenue
-98.05MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TBIO. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap24.5B
Illumina provides sequencing and array-based solutions for genetic analysis, directly competing in the genomics space with Telesis Bio's technologies.
Pacific Biosciences of California
PACB
Mkt Cap434.84M
Pacific Biosciences offers long-read sequencing technologies, competing with Telesis Bio in the genomic sequencing market.
CRISPR Therapeutics
CRSP
Mkt Cap5.33B
CRISPR Therapeutics is involved in gene editing, a direct competitor to Telesis Bio's gene editing and engineering solutions.
Editas Medicine
EDIT
Mkt Cap412.81M
Editas Medicine operates in the genome editing field, making it a competitor to Telesis Bio in the development of gene editing technologies.
Intellia Therapeutics
NTLA
Mkt Cap2.19B
Intellia Therapeutics is a leading gene editing company, competing with Telesis Bio in the CRISPR/Cas9 gene editing space.
Twist Bioscience
TWST
Mkt Cap5.45B
Twist Bioscience specializes in synthetic DNA, directly competing with Telesis Bio in the synthetic biology and gene synthesis market.
Sangamo Therapeutics
SGMO
Mkt Cap70.43M
Sangamo Therapeutics focuses on genomic medicine, including gene editing, competing in the same space as Telesis Bio.
Beam Therapeutics
BEAM
Mkt Cap3.51B
Beam Therapeutics is involved in base editing, a form of gene editing, positioning it as a competitor to Telesis Bio in the gene editing technology sector.
Adaptive Biotechnologies
ADPT
Mkt Cap2.81B
Adaptive Biotechnologies is focused on the immune-driven medicine space, indirectly competing with Telesis Bio by offering complementary and competing genomic and diagnostic solutions.

About

Telesis Bio, Inc., formerly known as Codex DNA, Inc. (and SGI-DNA, Inc. prior to that), is a San Diego, California-based synthetic biology company established in 2011. The company provides a comprehensive suite of instruments, reagents, and services for synthetic biology applications, catering primarily to pharmaceutical and academic laboratories worldwide. Its clientele also extends to government institutions, contract research organizations (CROs), and other synthetic biology enterprises. Among its core offerings is the BioXp system, a groundbreaking platform that empowers researchers to generate endpoint-ready synthetic DNA directly from digital sequences. Complementing this, the BioXp portal offers an intuitive online environment with guided workflows and design tools for constructing new DNA sequences and assembling them into desired vectors. For specific synthetic biology tasks, Telesis Bio supplies BioXp kits, which include essential building blocks and proprietary reagents like its well-known Gibson Assembly products. Additional solutions encompass cloud-based scripts and specialized benchtop reagents designed for post-BioXp system workflows. Through its Biofoundry Services, customers can commission and receive BioXp system-generated products, such as custom genes, clones, cell-free amplified DNA, and diverse variant libraries. The company also performs enzymatic DNA synthesis using short oligo ligation assembly techniques.
Show more...
CEO
Mr. Eric Esser
Employees
39
Country
United States
ISIN
US1920032000

Listings

0 Comments

Share your thoughts

FAQ

What is Telesis Bio stock price today?
The current price of TBIO is $0.00 USD — it has decreased by -0% in the past 24 hours. Watch Telesis Bio stock price performance more closely on the chart.
What is Telesis Bio stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Telesis Bio stocks are traded under the ticker TBIO.
Is Telesis Bio stock price growing?
TBIO stock has fallen by -0% compared to the previous week, the month change is a -0% fall, over the last year Telesis Bio has showed a -99% decrease.
What is Telesis Bio market cap?
Today Telesis Bio has the market capitalization of 1,776
What is Telesis Bio revenue for the last year?
Telesis Bio revenue for the last year amounts to 55.02M USD.
What is Telesis Bio net income for the last year?
TBIO net income for the last year is -98.05M USD.
How many employees does Telesis Bio have?
As of June 24, 2026, the company has 39 employees.
In which sector is Telesis Bio located?
Telesis Bio operates in the Health & Wellness sector.
When did Telesis Bio complete a stock split?
The last stock split for Telesis Bio was on May 09, 2024 with a ratio of 1:18.
Where is Telesis Bio headquartered?
Telesis Bio is headquartered in San Diego, United States.